Urogen Pharma Ltd Stock Research

Market Summary

USD11.43-0.08

Market Closed

-0.70%

URGN Stock Price

URGN RSI Chart

URGN Valuation

Market Cap

267.5M

Price/Earnings (Trailing)

-2.4

Price/Sales (Trailing)

3.93

EV/EBITDA

-2.11

Price/Free Cashflow

-2.98

URGN Price/Sales (Trailing)

URGN Profitability

Operating Margin

88.82%

EBT Margin

-171.63%

Return on Equity

172.81%

Return on Assets

-85.13%

Free Cashflow Yield

-33.51%

URGN Fundamentals

URGN Revenue

Revenue (TTM)

68.0M

URGN Earnings

Earnings (TTM)

-111.6M

Earnings Y/Y

-6.41%

Earnings Q/Q

-4.66%

Price Action

52 Week Range

4.8516.11

(Low)(High)

Last 7 days

-2.7%

Last 30 days

13.8%

Last 90 days

15.7%

Trailing 12 Months

107.4%

URGN Financial Health

Current Ratio

6.4

URGN Investor Care

Shares Dilution (1Y)

3.16%

Peers (Alternatives to Urogen Pharma)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
BGNE	326.1B	1.6B	-7.40%	77.06%	-170.12	209.44	77.54%	1.62%
ABBV	285.4B	56.7B	-12.25%	-1.83%	24.12	4.92	0.03%	-39.22%
REGN	87.6B	12.4B	-6.52%	9.77%	20.2	7.2	-25.07%	-47.28%
VRTX	85.9B	9.2B	0.73%	24.28%	26.35	9.33	15.86%	32.99%
ALNY	23.8B	1.0B	-8.34%	48.04%	-22.38	22.97	22.88%	-19.27%
SRPT	13.7B	975.7M	14.79%	105.15%	-12.27	14.02	27.41%	-212.78%
UTHR	10.1B	2.0B	-6.31%	2.88%	13.88	5.1	12.05%	52.86%
MID-CAP
MDGL	5.2B	504.0K	-7.03%	326.29%	-16.39	2.5K	-66.53%	-27.52%
RARE	3.6B	363.3M	21.73%	7.26%	-5.1	9.93	3.39%	-55.81%
BPMC	3.5B	204.6M	19.27%	2.79%	-6.08	17.28	-7.52%	10.65%
MRTX	2.7B	18.9M	7.20%	-28.12%	-3.61	140.65	-	-16.17%
SMALL-CAP
CYTK	3.7B	-	1.75%	-2.11%	-8.59	39.11	34.30%	-67.22%
CPRX	1.3B	256.5M	-26.70%	74.57%	12.87	4.99	66.85%	120.61%
MGNX	348.8M	165.3M	-18.85%	42.42%	-3.82	2.11	130.70%	57.97%
CRBP	46.0M	881.7K	23.42%	3374.52%	-0.91	19.11	-77.61%	-29.84%

Financials for Urogen Pharma

Income Statement (Last 12 Months)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Revenue	5.6%	67,985,000	64,357,000	62,439,000	57,693,000	54,121,000
Gross Profit	5.1%	59,591,000	56,703,000	55,459,000	51,489,000	48,336,000
S&GA Expenses	3.8%	86,012,000	82,838,000	82,622,000	85,175,000	86,646,000
R&D Expenses	-0.4%	52,708,000	52,906,000	51,511,000	50,341,000	49,825,000
EBITDA	4.6%	-106,350,000	-111,421,000	-110,703,000	-	-
EBITDA Margin	11.8%	-1.70	-1.93	-2.05	-	-
Earnings Before Taxes	-2.0%	-110,153,000	-108,028,000	-107,163,000	-112,252,000	-111,503,000
EBT Margin	11.8%	-1.72	-1.95	-2.06	-	-
Net Income	-1.7%	-111,604,000	-109,783,000	-109,366,000	-113,746,000	-113,277,000
Net Income Margin	11.2%	-1.75	-1.97	-2.09	-	-
Free Cahsflow	1.0%	-86,320,000	-87,225,000	-81,977,000	-	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Assets	-16.7%	113	136	128	146	166
Current Assets	-25.5%	96.00	129	122	140	161
Cash Equivalents	-34.1%	37.00	55.00	29.00	81.00	105
Inventory	26.4%	5.00	4.00	5.00	5.00	5.00
Net PPE	-15.0%	1.00	1.00	2.00	2.00	2.00
Liabilities	2.0%	230	225	192	187	183
Current Liabilities	5.5%	25.00	24.00	19.00	18.00	19.00
LT Debt, Non Current	0.4%	98.00	98.00	72.00	71.00	71.00
Shareholder's Equity	-30.4%	-116	-89.36	-17.07	-	-
Retained Earnings	-5.2%	-607	-577	-548	-522	-495
Additional Paid-In Capital	0.6%	491	488	485	481	479
Accumulated Depreciation	8.9%	3.00	3.00	2.00	-	-
Shares Outstanding	1.3%	23.00	23.00	23.00	23.00	23.00

Cashflow (Last 12 Months)					(In Thousands)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Cashflow From Operations	-2.1%	-89,370	-87,559	-85,877	-86,741	-81,487
Share Based Compensation	-6.3%	9,917	10,580	13,569	16,644	19,867
Cashflow From Investing	-691.1%	-6,266	1,060	-12,923	33,230	2,641
Cashflow From Financing	-72.1%	27,063	97,134	71,734	70,465	143,057

Risks for URGN

What is the probability of a big loss on URGN?

99.6%

Probability that Urogen Pharma stock will be more than 20% underwater in next one year

98.1%

Probability that Urogen Pharma stock will be more than 30% underwater in next one year.

73.8%

Probability that Urogen Pharma stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does URGN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Urogen Pharma was unfortunately bought at previous high price.

Drawdowns

Returns for URGN

Cumulative Returns on URGN

-28.3%

5-Year Cumulative Returns

-23.4%

3-Year Cumulative Returns

What are the long-term rolling returns for URGN?

FIve years rolling returns for Urogen Pharma.

Annualized Returns

Which funds bought or sold URGN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-05-22	AMERIPRISE FINANCIAL INC	unchanged	-	30,504	748,504	-%
2023-05-18	JPMORGAN CHASE & CO	added	8,576	552,000	558,000	-%
2023-05-16	JANE STREET GROUP, LLC	new	-	784,199	784,199	-%
2023-05-16	SUSQUEHANNA INTERNATIONAL GROUP, LLP	added	411	1,497,080	1,842,760	-%
2023-05-15	LAZARD ASSET MANAGEMENT LLC	unchanged	-	1,000	28,000	-%
2023-05-15	683 Capital Management, LLC	reduced	-15.94	-24,937	175,560	0.01%
2023-05-15	FIRST MANHATTAN CO. LLC.	unchanged	-	370	9,240	-%
2023-05-15	MILLENNIUM MANAGEMENT LLC	added	27.96	819,000	3,278,000	-%
2023-05-15	STATE STREET CORP	reduced	-46.61	-886,495	1,110,850	-%
2023-05-15	Annandale Capital, LLC	unchanged	-	31,000	779,000	0.25%

Latest Funds Activity

Are funds buying URGN calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own URGN

No. of Funds

Urogen Pharma News

Schedule 13G FIlings of Urogen Pharma

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2023	stonepine capital management, llc	5.7%	1,304,947	SC 13G/A
Dec 01, 2022	stonepine capital management, llc	5.2%	1,196,908	SC 13G
Jul 08, 2022	blackrock inc.	1.5%	340,412	SC 13G
Feb 14, 2022	wildcat capital management, llc	2.4%	533,139	SC 13G/A
Feb 14, 2022	credit suisse ag/	4.84%	1,085,749	SC 13G/A
Feb 04, 2022	wellington management group llp	1.06%	238,008	SC 13G/A
Feb 03, 2022	blackrock inc.	7.7%	1,728,094	SC 13G/A
Feb 12, 2021	credit suisse ag/	07%	1,121,071	SC 13G
Feb 12, 2021	wildcat capital management, llc	2.41%	533,139	SC 13G/A
Feb 11, 2021	menora mivtachim holdings ltd.	13.37%	2,954,699	SC 13G/A

URGN Fair Value

Urogen Pharma fair value in different scenarios

The table shows the Fair Value estimates for Urogen Pharma for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	- -	- -	1.82 -84.08%	4.00 -65.00%	12.28 7.44%
Current Inflation	- -	- -	0.21 -98.16%	3.00 -73.75%	10.11 -11.55%
Very High Inflation	- -	- -	0.75 -93.44%	1.83 -83.99%	7.57 -33.77%

Historical Urogen Pharma Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of Urogen Pharma

View All Filings

Date Filed	Form Type	Document
May 11, 2023	8-K	Current Report
May 11, 2023	10-Q	Quarterly Report
May 01, 2023	10-K/A	Annual Report
Mar 24, 2023	10-K	Annual Report
Mar 22, 2023	8-K	Current Report
Feb 28, 2023	4/A	Insider Trading
Feb 28, 2023	4/A	Insider Trading
Feb 28, 2023	4	Insider Trading
Feb 13, 2023	SC 13G/A	Major Ownership Report

Latest Insider Trading transactions for URGN

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-01-31	Schoenberg Mark	acquired	-	-	3,833	chief medical officer
2023-01-31	Barrett Elizabeth A.	acquired	-	-	18,333	chief executive officer
2023-01-31	Smith Jason Drew	sold	-16,556	10.12	-1,636	general counsel
2023-01-31	Schoenberg Mark	sold	-19,228	10.12	-1,900	chief medical officer
2023-01-31	Smith Jason Drew	acquired	-	-	3,333	general counsel
2023-01-20	Schoenberg Mark	acquired	613,385	5.00	122,677	chief medical officer
2022-10-31	Schoenberg Mark	acquired	-	-	500	chief medical officer
2022-10-31	Schoenberg Mark	sold	-3,057	11.85	-258	chief medical officer
2022-10-21	Nussbaum Ran	acquired	285,114	5.94	47,999	-

About Urogen Pharma

Elizabeth Barrett

200

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

URGN Income Statement

2023-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue	$ 17,192	$ 13,564
Cost of revenue	2,265	1,525
Gross profit	14,927	12,039
Operating expenses:
Research and development expenses	12,498	12,696
Selling, general and administrative expenses	24,474	21,300
Operating loss	(22,045)	(21,957)
Financing on prepaid forward obligation	(5,224)	(5,826)
Interest expense on long-term debt	(3,553)	(282)
Interest and other income (expense), net	630	(2)
Loss before income taxes	(30,192)	(28,067)
Income tax expense	(21)	(325)
Net Loss	(30,213)	(28,392)
Statements of Comprehensive Loss
Net loss	(30,213)	(28,392)
Other comprehensive loss
Unrealized gain (loss) on investments	62	(44)
Comprehensive Loss	$ (30,151)	$ (28,436)
Net loss per ordinary share - basic and diluted (in dollars per share)	$ (1.30)	$ (1.25)
Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share (in shares)	23,279,951	22,631,509

URGN Balance Sheet

2023-03-31

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 36,540	$ 55,408
Marketable securities	28,514	44,556
Restricted cash	814	813
Accounts receivable	12,493	12,704
Inventories	5,466	4,325
Prepaid expenses and other current assets	12,146	11,101
Total current assets	95,973	128,907
Non-current assets:
Property and equipment, net	1,103	1,297
Restricted deposit	224	223
Right of use assets	2,329	2,452
Marketable securities	10,165	0
Other non-current assets	3,160	2,740
Total Assets	112,954	135,619
Current liabilities:
Accounts payable and accrued expenses	17,130	12,383
Employee related accrued expenses	4,919	8,257
Other current liabilities	3,185	3,276
Total current liabilities:	25,234	23,916
Non-current liabilities:
Prepaid forward obligation	101,912	98,923
Long-term debt	97,941	97,537
Long-term lease liabilities	1,403	1,586
Uncertain tax positions liability	3,018	3,018
Total Liabilities	229,508	224,980
Commitments and Contingencies (Note 18)
Shareholders' Deficit:
Ordinary shares, NIS 0.01 par value, 100,000,000 shares authorized at March 31, 2023 and December 31, 2022; 23,440,521 and 23,129,953 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively	64	63
Additional paid-in capital	490,744	487,787
Accumulated deficit	(607,317)	(577,104)
Accumulated other comprehensive loss	(45)	(107)
Total Shareholders' Deficit	(116,554)	(89,361)
Total Liabilities and Shareholders' Deficit	$ 112,954	$ 135,619